Oncology Learning Network

Oncology Learning Network
Combo Therapy May Target MET-Dependent Resistance in RET+ NSCLC

With the help of single patient protocols, researchers discover that combining selpercatinib with crizotinib targets MET-amplified resistance found in RET+ NSCLC treated with selpercatinib alone.

Oncology Learning Network
Cemiplimab Therapy Safe, Active in Patients With Cutaneous Squamous Cell Carcinoma

Phase 2 study findings demonstrated the acceptable safety profile and antitumor activity of cemiplimab therapy for patients with locally advanced cutaneous squamous cell carcinoma.

Oncology Learning Network
Triplet Combo Regimen Yields Significant Clinical Benefit in Relapsed/Refractory MM

Real-world study findings presented at the virtual ESMO Congress show that therapy with ixazomib plus lenalidomide and dexamethasone yields significant clinical benefits...

Oncology Learning Network
Bortezomib-Based Triplet Therapy Shows No Benefit Over Doublet for MM With Acute Kidney Injury

Comparison of bortezomib-based triplet therapy regimen to a bortezomib doublet regimen shows no benefit in adding C-BD over BD for renal recovery in patients with MM and acute kidney injury.

Oncology Learning Network
Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC

Dr. Solange Peters provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what these findings mean for the treatment of patients with NSCLC.

Oncology Learning Network
Researchers Demonstrate Promising Efficacy of Lorlatinib in Patients With ALK+ NSCLC

Dr. David Carbone offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive non–small-cell lung cancer.

Oncology Learning Network
Long-Lasting Remission With Dual Targeting CAR-T Therapy for R/R DLBCL

Patients with relapsed/refractory DLBCL given AUTO3 in combination with pembrolizumab experienced durable complete remissions, according to data presented by Aravind Ramakrishnan, MD.

Oncology Learning Network
ViPOR Yields Complete Response in Patients with R/R B-Cell NHL

In a phase 1b/2 study of patients with relapsed/refractory B-cell non-Hodgkin's lymphoma, the ViPOR regimen led to complete responses, with no unexpected toxicities.

Oncology Learning Network
Exploring Dosing Regimens of Sabatolimab Therapy for MDS/AML

Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS or AML.

Oncology Learning Network
Better EFS With Blinatumomab vs Chemo for High-Risk First Relapse of BCP-ALL

This study suggests blinatumomab monotherapy as a new standard-of-care consolidation therapy before allogeneic hematopoietic stem cell transplant in young patients with high-risk first-relapse BCP-

Oncology Learning Network
Subscribe to Oncology Learning Network

source list reference